Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
22 March 2024Website:
http://www.lenz-tx.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
after hours | Thu, 20 Jun 2024 20:00:08 GMTDividend
Analysts recommendations
Institutional Ownership
LENZ Latest News
Lenz Therapeutics said on Wednesday its experimental drugs to treat loss of near vision met the main goal of a late-stage study, sending its shares up nearly 23% before the bell.
What type of business is LENZ Therapeutics?
LENZ Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
What sector is LENZ Therapeutics in?
LENZ Therapeutics is in the Healthcare sector
What industry is LENZ Therapeutics in?
LENZ Therapeutics is in the Biotechnology industry
What country is LENZ Therapeutics from?
LENZ Therapeutics is headquartered in United States
When did LENZ Therapeutics go public?
LENZ Therapeutics initial public offering (IPO) was on 22 March 2024
What is LENZ Therapeutics website?
https://www.lenz-tx.com
Is LENZ Therapeutics in the S&P 500?
No, LENZ Therapeutics is not included in the S&P 500 index
Is LENZ Therapeutics in the NASDAQ 100?
No, LENZ Therapeutics is not included in the NASDAQ 100 index
Is LENZ Therapeutics in the Dow Jones?
No, LENZ Therapeutics is not included in the Dow Jones index
When does LENZ Therapeutics report earnings?
Next earnings report date is not announced yet